CURRICULUM VITAE
DOUGLASS W. FORSHA, M.D.

OFFICE: Jordan Valley Dermatology Center
10654 S. River Heights Dr. Ste 210
South Jordan, UT 84095
Phone: (801) 569-1456
Research Direct phone: (801) 316-0266
FAX: (801) 565-7931
Email: dforsha@jvderm.com

DEGREES EARNED

M.D.: Vanderbilt University School of Medicine, Nashville, Tennessee – 1985
B.A. (cum laude): Asian Studies – Brigham Young University, Provo, Utah – 1979

EDUCATION

Residency: Dermatology – University of Illinois College of Medicine at Chicago – 1986 – 1989
Postgraduate Internship: Internal Medicine – Vanderbilt University and Affiliated Hospitals – 1985 – 1986
Graduate: Vanderbilt University School of Medicine – 1981 – 1985
Undergraduate: Brigham Young University, Provo, Utah – 1973 – 1979

PROFESSIONAL MEMBERSHIPS

American Academy of Dermatology
American Medical Association

EXPERIENCE

Jordan Valley Dermatology, West Jordan, Utah – January 2014-Current
Medical Director and Principal Investigator
Founded South Valley Dermatology, West Jordan, Utah – July 1991-Current
Medical Director and Principal Investigator
Dermatology practice at Aiken Dermatology and Skin Cancer Clinic
Aiken, South Carolina – July 1989 – July 1991

CERTIFICATION AND LICENSURE

GCP Certified – Expires July 2025
Medical License – State of Utah (1056010010) – State of Wyoming (8010A)
National Board of Medical Examiners – Diplomate – 1986

2/12/25

HOSPITAL PRIVILEGES

Intermountain Medical Center, Murray, Utah – Courtesy Staff
Jordan Valley Medical Center, West Jordan, Utah – Active Staff
Pioneer Valley Hospital, West Valley City, Utah – Active Staff

Co-Author

Boguniewicz, M., Paller, A. S., Tom, W. L, Lebwohl, M. G., Blumenthal, R. L, Call, R. S., ... Gold, LF.S. (2016). Efficacy and Safety of Crisaborole Topical Ointment, 2%, a Novel, Nonsteroidal, Topical, Anti-Inflammatory, Phosphodiesterase Inhibitor in 2 Phase 3 Studies in Children and Adults with Mild-to-Moderate Atopic Dermatitis. Journal of Allergy and Clinical Immunology, 137(2), AB397. doi:10.1016/j.jaci.2015.12.1230

Eichenfield, L F., Call, R. S., Forsha, D. W., Fowler, J., Hebert, A. A., Spellman, M., ... Tschen, E. (2017). Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. Journal of the American Academy of Dermatology, 77(4), 641-649.e5. doi:10.1016/j. jaad.2017.06.010

Hebert, A., Glaser, D. A., Green, L, Werschler, W. P., Forsha, D. W., Drew, J., Gopalan, R. & Pariser, D. M. (2018). Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials. Pediatric Dermatology, 36(1), 89-99. doi:10.1111/pde.13723

Paller, A. S., Tom, W. L, Lebwohl, M. G., Blumenthal, R. L, Boguniewicz, M., Eichenfield, L. F., Call, R. S., ... Hebert, A. A. (2016). Crisaborole topical ointment, 2%: Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. Journal of the American Academy of Dermatology, 75(3), 494-503.e6. doi:10.1016/j.jaad.2016.05.046

Paller, A. S., Tom, W. L, Lebwohl, M. G., Blumenthal, R. L, Boguniewicz, M., Eichenfield, L S., ... Hebert, A. A. (2017). Crisaborole topical ointment, 2%: A novel, nonsteroidal, topical antiinflammatory, phosphodiesterase 4 inhibitor: results from two phase 3 studies treating children and adult patients with mild to moderate atopic dermatitis. Journal of the American Academy of Dermatology, 76(4), 777. doi:10.1016/j.jad.2016.05.046

Zane, L T., Eichenfield, L F., Call, R. S., Forsha, D. W., Fowler, J. F., Hebert, A. A., ... Tschen, E. H. (2016). Long-term safety of crisaborole topical ointment, 2%, in children and adults with mild-to-moderate atopic dermatitis. The Journal of Immunology, 196(1 Supplement), 191.28. Retrieved from http://www.jimmunol.org/content/196/1_Supplement/191.28

Zane, L T., Paller, A. S., Tom, W. L, Lebwohl, M. G., Blumenthal, R. L, Boguniewicz, M., ... Simpson, E.L (2016). Two phase 3 study results of children and adults with mild-to-moderate atopic dermatitis treated with Crisaborole Topical Ointment, 2%, a novel, nonsteroidal, topical, anti-inflammatory, phosphodiesterase 4 inhibitor. The Journal of Immunology, 196(1 Supplement), 191.26. Retrieved from http://www.jimmunol.org/content/196/1_Supplement/191.26

POSTER SESSIONS

American Academy of Dermatology (AAD) Annual Meeting
March 4, 2017
Orlando, Florida
Crisaborole topical ointment, 2%: A novel, nonsteroidal, topical anti-inflammatory, phosphodiesterase 4 inhibitor: Results from two phase 3 studies treating children, adults with atopic dermatitis
Summary: In these two phase 3 clinical trials, researchers evaluated the efficacy and safety of crisaborole topical ointment, 2%, in children and adults with mild to moderate atopic dermatitis (AD), and concluded that this ointment had favorable efficacy and safety in patients as young as 2 years old with mild to moderate AD.

MauiDerm
January 25-29, 2016
Maui, Hawaii
Results from two Phase 3 studies in children and adults with mild-to-moderate Atopic Dermatitis treated withi Crisaborole Topical Ointment, 2%, a novel nonsteroidal, topical anti-inflammatory, Phosphodiesterase 4 inhibitor
Summary: Crisaborole Topical Ointment, 2%, demonstrated favorable efficacy and safety in two large Phase 3 studies and may represent a safe and efficacious treatment for patient as young as two years with mild-to-moderate AD.

16th Annual Las Vegas Dermatology Seminar: Scientific Abstract,
November 5-7, 2015
Las Vegas, Nevada
PA-11: Crisaborole topical ointment 2%, a novel nonsteroidal, topical, anti-inflammatory, phosphodiesterase 4 inhibitor: results in children and adults with mild-to-moderate atopic dermatitis from two phase 3 studies
Conclusion: in 2 large Phase 3 studies, favorable efficacy and safety was demonstrated for Crisaborole Topical Ointment, 2%. It may represent a novel, safe, and efficacious treatment for patients as young as 2 years with mild-to-moderate AD.

OTHER ACTIVITIES

Chief Organist at church in Aiken, South Carolina
Lived in Thailand 1974 – 1976 – Speak fluent Thai
Member of the Mormon Tabernacle Choir, Salt Lake City, Utah – 1973 – 1974
Enjoy snow skiing, swimming and racquetball

PREVIOUS AND ONGOING RESEARCH EXPERIENCE
DOUGLASS WILLIAM FORSHA, M.D.

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis.
Sponsor: Alumis

A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants with Moderate to Severe Hidradenitis Suppurativa.
Sponsor: Eli Lilly

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ – CSU2)
Sponsor: Celldex

A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children from 2 to Less than 12 Years of Age with Moderate to Severe Atopic Dermatitis.
Sponsor: Abbvie

A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)
Sponsor: Amgen

A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneous sonelokimab in adult participants with moderate to severe hidradenitis suppurativa
Sponsor: Moonlake

A Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Ruxolitinib Cream in Pediatric Participants with Nonsegmental Vitiligo
Sponsor: Incyte

AN OPEN-LABEL MULTI-DOSE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VDPHL01 IN MALE SUBJECTS WITH ANDROGENETIC ALOPECIA
Sponsor: Veradermics

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Male Subjects with Androgenetic Alopecia
Sponsor: Veradermics

A Randomized, Double-Blind, Vehicle-Controlled Phase 2b Trial Evaluating the Efficacy, Safety & Pharmacokinetics of VYN201 Gel in the Treatment of Non-Segmental Vitiligo
Sponsor: Vyne

A Randomized, Multicenter, Double-blind, Vehicle-controlled, Phase 2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of PP405 in Adults with Androgenetic Alopecia
Sponsor: Pelage

A phase 2b multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of an oral treatment for participants with moderate to severe plaque psoriasis.
Sponsor: Janssen

A Phase 2, International, Multicenter, Randomized, Doubleblind, Placebo-controlled, Dose-ranging study of Efficacy and Safety of SAR441566 in Adults with Moderate to Severe Plaque Psoriasis.
Sponsor: Sanofi

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 18 years and older with moderate-to-severe atopic dermatitis.
Sponsor: Sanofi

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 18 years and older with moderate-to-severe atopic dermatitis on background topical corticosteroids.
Sponsor: Sanofi

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects with Atopic Dermatitis.
October 2023/October 2024
Sponsor: Escient Pharmaceuticals

A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Proof-of-Concept Trial of ADX-914 for the Treatment of Severe Alopecia Areata.
Sep 2023/Current
Sponsor: Q32 Bio Inc.

A Multi-center, randomized, double-blind, placebo controlled study evaluating the effect of Deucravacitinib on quality of life in participants with plaque psoriasis in a community setting (ARTISTYK).
Mar 2023/ 2024
Sponsor: Bristol-Myers Squibb Company

An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults with Atopic Dermatitis Experiencing Sleep Disturbance in the United States (Morpheus)
Mar 2023/Dec 2024
Sponsor: Incyte

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study to Evaluate Clinical Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants with Alopecia Areata.
Aug 2022/2024
Sponsor: Bristol-Myers Squibb Company

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis
Nov 2022/2023
Sponsor: Alumis

A Phase 2 Clinical Trial to Evaluate the Safety, Clinical Effects, and Systemic Exposure of a Topical Application of BMX-010 Ointment in Adult Subjects with Atopic Dermatitis
Nov 2022/2023
Sponsor: BioMimetix

A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages ≥ 12 Years to < 18 Years) With Atopic Dermatitis
Sep 2022/2024
Sponsor: Incyte

A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lupus Erythematosus (Subacute Cutaneous Lupus Erythematosus and/or Discoid Lupus Erythematosus) Participants Receiving Standard of Care.
May 2022/ 2023
Sponsor: Merck

A Phase 3, Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% Applied to a Field of Approximately 100 cm2 on the Face or Balding Scalp in Adult Patients with Actinic Keratosis.
May 2022/ 2022
Sponsor: Almirall

A Phase 2 study to evaluate the efficacy and safety of RPT193 as monotherapy in adults with moderate-to-severe atopic dermatitis.
May 2022/ 2024
Sponsor: Rapt Therapeutics

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients with Moderate-to-Severe Atopic Dermatitis.
Apr 2022/ 2023
Sponsor: Aslan

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX in Adult Patients with Moderate to Severe Alopecia Areata.
Apr 2021/2022
Sponsor: Concert Pharmaceuticals

An Open Label, Phase 1, Pharmacokinetics, Maximal Usage Pharmacokinetics, Safety, and Efficacy Study of ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% Administered QD in Adolescent and Pediatric Subjects with Mild to Moderate Atopic Dermatitis
Jul 2021/2023
Sponsor: Arcutis

A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of XXX Foam 0.3% Administered QD in Subjects with Seborrheic Dermatitis.
Apr 2021/2023
Sponsor: Arcutis

A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of XXX Cream 0.15% and XXX Cream 0.05% in Subjects with Atopic Dermatitis.
Apr 2021/2022
Sponsor: Arcutis

A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of XXX Cream 0.15% Administered QD in Subjects with Atopic Dermatitis.
Mar 2021/2022
Sponsor: Arcutis

A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of XXX Cream 0.05% Administered QD in Subjects with Atopic Dermatitis.
Apr 2021/2022
Sponsor: Arcutis

A Phase 2a, Proof of Concept, 24-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of XXX Cream 0.3% in Subjects with Non-Segmental Facial Vitiligo
Mar 2021/2022
Sponsor: Arcutis

A Randomized, Double-Blind, Multicentric, Parallel Group Therapeutic Equivalence Study Comparing Efficacy, Safety and Immunogenicity of Subcutaneous XXX and EU Sourced Stelara in Patients with Moderate to Severe Chronic Plaque Psoriasis.
Mar 2021/2023
Sponsor: Dong-A ST

A Randomized, Double-Blind, Vehicle-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of XXX and XXX in the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Photodynamic Therapy (PDT)
Mar 2021/Current
Sponsor: Biofrontera

Corrona Psoriasis (PSO) Registy
Nov 2020/Current
Sponsor: Corrona

A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients with Moderate-To-Severe Atopic Dermatitis.
Nov 2020/2022
Sponsor: Eli Lilly and Company

A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients with Moderate-to-Severe Atopic Dermatitis
Oct 2020/2022
Sponsor: Eli Lilly and Company

A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and Vehicle Gel Once Daily in the Treatment of Molluscum Contagiosum
Sep 2020/2021
Sponsor: Novan, Inc.

A PHASE 2B/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, EFFICACY, AND SAFETY STUDY IN PRURIGO NODULARIS WITH XXX TABLETS FOR PRURITUS RELIEF THROUGH ITCH SCRATCH MODULATION (PRISM STUDY)
Jul 2020/2022
Sponsor: Trevi Therapeutics, Inc.

A Multicenter, Randomized, Placebo and Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of XXX in Pediatric Subjects from 6 to <18 Years of Age with Moderate to Severe Chronic Plaque Psoriasis
Jan 2020/2023
SPONSOR: Sun Pharmaceutical Global FZE

A Phase 3B Randomized, Double-Blind, Double-Dummy, Active Controlled Multi-Center Study Assessing the Efficacy and Safety of XXX Compared with XXX in Adult Participants on Background Topical Therapy with Moderate to Severe Atopic Dermatitis
Jul2020/2021
SPONSOR: Pfizer, Inc.

A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction with XXX Ointment, 2%, Once Daily Over 52 Weeks in Pediatric and Adult Participants (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis, who Responded to Twice Daily XXX Ointment, 2%, Treatment
Dec 2019/2020
SPONSOR: Pfizer, Inc.

A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of XXX Cream 0.3% Administered QD in Subjects with Chronic Plaque Psoriasis
Feb 2020/2021
SPONSOR: Arcutis Inc.

A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of XXX Cream 0.3% in Subjects with Chronic Plaque Psoriasis who have Completed Preceding Studies XXX-301 or XXX-302
Feb 2020/2021
SPONSOR: Arcutis Inc.

A Randomized, Double-Blind, Placebo-Controlled, Efficacy Study of the Neurokonin-Receptor Antagonist XXX in Patients with Atopic Dermatitis
Nov 2019/2020
SPONSOR: Vanda Pharmaceuticals Inc.

A Phase 3 Efficacy and Safety Study of XXX for the Treatment of Plaque Psoriasis in Adults
July 2019/July 2020
SPONSOR: Dermavant Sciences, Inc

A Long-Term, Open-Label, Extension Study to Evaluate the Safety and Efficacy of XXX Cream, 1% for the Treatment of Plaque Psoriasis in Adults
July 2019/Aug 2021

SPONSOR: Dermavant Sciences, Inc

A Phase 3 Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Centered Study Investigating the Efficacy and Safety of XXX and XXX in Comparison with Placebo in Adult Subjects on Background Topical Therapy, with Moderate to Severe Atopic Dermatitis
May 2019/May 2020
SPONSOR: Pfizer, Inc.

A Phase 3 Multi-Center, Long-Term Extension Study Investigating the Efficacy and Safety of XXX, With or Without Topical Medications, Administered to Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis May 2019/Current
SPONSOR: Pfizer, Inc.

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXX in Pediatric Subject form 6 Through 17 years of Age with Moderate to Severe Plaque Psoriasis.
Dec 2018/ 2022
SPONSOR: Celgene

A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of xxx Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis.
Feb 2019/Mar 2021
SPONSOR: Incyte

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter dose-ranging study to assess the safety and efficacy of multiple oral XXX doses in patients with moderate to severe atopic dermatitis (ZEST trial).
Dec 2018/2019
SPONSOR: Novartis

A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of XXX in the Treatment of Acne Vulgaris
Mar 2019/2020
SPONSOR: Sol-Gel Technologies, Ltd

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist XXX in Subject with Atopic Dermatitis.
July 2018/2019
SPONSOR: Vanda

A Phase 2, A Pilot Evaluation of a Novel Therapy (Drug and Device) to Promote Hair Growth in Androgenetic Alopecia (AGA): A Prospective, Multicenter, Randomized Study.
Mar 2018/2020
SPONSOR: Follica

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of XXX in Adult Patients with Moderate to Severe Atopic Dermatitis
May 2018/Sept 2019
SPONSOR: Eli Lilly and Company

A Phase 4, Multicenter Open-label Safety Study of XXX Ointment, 2% in Children Aged 3 months to less than 24 months with Mild to Moderate Atopic Dermatitis
Jan 2018/May 2019
SPONSOR: Pfizer, Inc.

A Multicenter, Double-Blind, Nontreatment, Long-term, Follow-up Study of Subjects Who Completed Clinical Studies 755.1100_FA, 810.1100_FA, or 1064.1100_FA of a Topical XXX Solution Followed by Laser for the Treatment of Facial Acne Vulgaris
Device
Phase Pivotal
May 2018/Mar 2019
SPONSOR: Sienna

Clinical Investigation of a Topical XXX Solution Followed by 755 nm Laser for the Treatment of Acne Vulgaris in Facial Areas of Subjects
Device
Phase Pivotal
Jan 2018/Mar 2019
SPONSOR: Sienna

A Double-Blind Clinical Investigation of the Efficacy and Safety of XXX Used in Conjunction with Laser for Light-Hair Removal
Device
Phase Pivotal
August 2017/Sep 2019
SPONSOR: Sienna

A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of XXX Lotion and XXX Vehicle Lotion in the Treatment of Acne Vulgaris
Phase III
July 2017/July 2018
SPONSOR: Valeant/CuTech

Evaluation of efficacy, duration of remission and safety of a light and occlusive patch therapy for plaque psoriasis.
Device
Dec 2016/ Oct 2018
SPONSOR: Luma Therapeutics, Inc.

A Randomized, Prospective, Multicenter, Double Blind, Parallel Assignment, Placebo Controlled Bioequivalence Study of XXX Cream, 1% and XXX Cream, 1% in Patients with Mild to Moderate Atopic Dermatitis.
Dec 2016/Aug 2017
SPONSOR: DPT Laboratories, Ltd., a Division of Mylan

A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of XXX for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris, Study XXX
Jun 2016/Jan 2018
SPONSOR: Foamix Pharmaceuticals

A randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability of 8 –week Regimens XXX, 10% Topical Solution (Taro Pharmaceuticals, USA, Inc.) in Patients with Mild to Moderate Onychomycosis
Mar 2016/Mar 2018

SPONSOR: Taro Pharmaceuticals, USA

XXX versus placebo In a Multicenter randomized double-blind study in patients with Moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomized withdrawal and re-treatment
Mar 2016/May 2016
SPONSOR: Boehringer Ingelheim

An Open-label Study to Evaluate the Safety and Tolerability of XXX topical solution, 5% in the Treatment of Onychomycosis of the Toenail in Pediatric Patients Aged 6 to 16 Years and 11 Months.
March 2016/Nov 2017
SPONSOR: Anacor

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of XXX in Treatment-Resistant Pruritus Associated with Atopic Dermatitis
Mar 2016/Oct 2017
SPONSOR: Vanda Pharmaceuticals, Inc.

A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Nov 2015/Feb 2017
SPONSOR: Dow Pharmaceutical Sciences, a Division of Valeant Pharmaceuticals North America, LLC

A Randomized, Double-Blind, Parallel-Design, Muti-Site Study to Evaluate the Therapeutic Equivalence of XXX XXX Gel 3% (Taro Pharmaceuticals USA, Inc.) Compared to XXX 3% Gel (XXX XXX 3% w/w; Almirall, S. A.) in the Treatment of Actinic Keratosis Bioequivalence study
Jul 2015/Apr 2016
SPONSOR: Novum

A Phase 3, Randomized, Double-blind, Vehicle-Controlled Efficacy and Safety Study of XXX in Subjects with Axillary Hyperhidrosis
Aug 2015/July 2016
SPONSOR: Dermira

An Open-Label Study Assessing Long-Term Safety of XXX in Subjects with Primary Axillary Hyperhidrosis
Aug 2015/ Mar 2017
SPONSOR: Dermira

A Multi-Center, Double-Blind, Randomized Vehicle-Controlled, Parallel- Group Study to Compare XXX XXX Cream, 5% with XXX (XXX) Cream 5%, and both Active Treatments to a Vehicle Control in Treatment of Recurrent Herpes Simplex Labialis
Bioequivalance study
Nov 2014/May 2016
SPONSOR: Perrigo

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous XXX [300 mg] as assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects with Moderate to Severe Scalp Psoriasis Phase III

Dec 2014/May 2016
SPONSOR: Novartis

A Prospective, Observational Study to Estimate the Proportion of Subjects with Plaque Psoriasis who Achieve Complete Clearance On Biologics
May 2014/Mar 2016
SPONSOR: Amgen

A Randomized, Multicenter, Double Blind, Phase III, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5mg/kg per Day of XXX Compared to Placebo in the Treatment of Acne Vulgaris
Nov 2014/Feb 2017
SPONSOR: Warner/Chilcott/Allergan

A Multi-Center Open-Label Evaluation of the Safety of XXX Tablets in the Treatment of Acne Vulgaris
May 2015/Sept 2016
SPONSOR: Warner/Chilcott/Allergan

A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled Study of the Safety and Efficacy of XXX 3mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 years of age) with Mild to Moderate Plaque Psoriasis
Phase IV
Jun 2014/Apr 2016
SPONSOR: Galderma

XXX, A Phase 2, Randomized, Double-Blind, Multicenter, Parallel Group, Placebo Controlled Study to Assess the Efficacy and Safety of 3 Dose Levels of XXX in Subjects with Chronic Plaque-type Psoriasis
Aug 2014/Sep 2015
SPONSOR: XenoPort

A Randomized, Double-blind, Placebo Controlled Study to Demonstrate the Efficacy and Long Term Safety of XXX in Adult Patients with Moderate to Severe Atopic Dermatitis
Phase 3
Nov 2014/May 2015
SPONSOR: Regeneron

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of XXX Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
Phase III
Apr 2014/Aug 2015
SPONSOR: Anacor

A Multicenter, Open-Label Study of the Long-Term Safety of XXX Topical Ointment, 2% in the Treatment of Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
Phase III
Jun 2014/November 2015
SPONSOR: Anacor

A Safety and Efficacy Study to Compare XXX Dermal Gel with Vehicle Control in Patients with Acne Vulgaris

Phase III
Feb 2014/Dec 2014
SPONSOR: Allergan

A Phase IV, Open-Labeled, Photographic Study with Acne Patients with Severe Recalcitrant Nodular Treated with XXX (XXX) Capsules
Feb 2014/May 2015
SPONSOR: Ranbaxy

A Phase IV, Open-Labeled, Photographic Study with Acne Patients with Severe Recalcitrant Nodular Treated with XXX (XXX) Capsules
May 2015/Apr 2018
SPONSOR: Ranbaxy

A 52 –Week, Phase III, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous of XXX XXX/XXX, Followed by an Optional Long-Term Safety Extension Study, in Subjects with Moderate-to-Severe Chronic Plaque Psoriasis
Jul 2013/Current
SPONSOR: Merck

A 264-week Multlicenter, Randomized, Double-blind, Placebo-Controlled Study Comparing the Efficacy and Safety of XXX to XXX and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis with a Long-term Extension Period
Phase III Biologic
Sep 2012/Current
SPONSOR: Eli Lilly

A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of XXX Capsules in Adult Subjects with Atopic Dermatitis
Phase II
Aug 2013/Apr 2014
SPONSOR: Asubio

A Phase III Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of XXX Compared with Placebo and XXX in Subjects with Moderate to Severe Plaque Psoriasis
Biologic
Nov 2012/Mar 2016
SPONSOR: Amgen

Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study Comparing XXX XXX Gel 3% (XXX) to XXX (XXX XXX) Gel 3% (XXX XXX) in the Treatment of Actinic Keratosis.
Mar 2013/Sep 2013
SPONSOR: Novum

A Randomized, Double-blind, Placebo-controlled, Multiple-site Study Comparing XXX Topical Gel 1% (XXX XXX XXX) to XXX (XXX gel) 1% (XXX) in the Treatment of Moderate-to-Severe Rosacea
Phase III

Aug 2011/May 2012
SPONSOR: Novum

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study of XXX in the Treatment of Recurrent Herpes Labialis
Phase III
Apr 2011/Jan 2012
SPONSOR: NanoBio Corporation

A Phase 2, Multicenter, Double-Blind, Dose-Ranging Study to Evaluate XXX Versus Placebo in the Treatment of Severe Acne Vulgaris With Nodules
Sep 2010/Dec 2011
SPONSOR: Dow

Phase III Study Evaluating XXX Cream 5% Compared to XXX 5% Cream in Patients with Actinic Keratosis
Feb 2009/Dec 2009
SPONSOR: Novum

Phase IV Study Evaluating XXX Emulsion in the Clinic When Used as Monotherapy for Atopic Dermatitis. Completed March 2010.
SPONSOR: Promius Pharma

A Phase 4, Open-Label, Multicenter, Community-based, 12-Week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction With XXX® [XXX, USP] Capsules 40 mg (30 mg Immediate Release & 10 mg Delayed Release Beads) When Used as Monotherapy or as Add-On Therapy to Existing Topical Regimens for the Treatment of Rosacea
April 2009/Nov 2009
SPONSOR: Galderma

A Phase II, Multi-Center, Double-Blind, Randomized, Dose-ranging Study to Evaluate XXX Versus Placebo in the Treatment of Severe Acne Vulgaris with Nodules
Mar 2008/Jul 2009
SPONSOR: Dow

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of 2 Doses of XXX (400 mg BID and 800 mg BID) in Patients With Atopic Dermatitis
Phase II
May 2008/Dec 2009
SPONSOR: Shiongi USA

A Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year after Completion of Studies XXX, XXX, XXX, and XXX
May 2008/Oct 2009
SPONSOR: Graceway Pharmaceuticals

A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter, Efficacy and Safety Study of Six Weeks of Treatment With Imiquimod Creams for Actinic Keratoses
Jan 2008/Aug 2008

SPONSOR: Graceway Pharmaceuticals

A Multi-Center, Randomized, Double-Blind, Active-Control Clinical Triall to Determine the Effects of XXX XXX Modified Release Capsules, 40mg (COL-101) Administered Once Daily in Conjunction with XXX (XXX topical gel, 1%) vs XXX XXX Immediate-Release Capsules, 100mg Administered Once Daily in Conjunction with XXX (XXX topical gel, 1%) in Patients with Moderate to Severe Rosacea
Feb 2007/Jan 2008
SPONSOR: CollaGenex Pharmaceuticals

Observational Post-marketing Safety Surveillance Registry of XXX (XXX) for the Treatment of Psoriasis.
May 2006/Feb 2013
SPONSOR: Amgen

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study of XXX in the Treatment of Recurrent Herpes Labialis
May 2011/Apr 2012
SPONSOR: NanoBio Corporation

The Safety, Pharmacokinetics and Efficacy of XXX, 0.1%, 0.3%, 0.5% in Subjects with Recurrent Herpes Labialis.
Feb 2007/Dec 2007
SPONSOR: NanoBio Corporation

A Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of XXX Tablets, XXX Capsules and Placebo in the Treatment of Onychomycosis of the Toenail
Dec 2006/Jan 2009
SPONSOR: Barrier Therapeutics

Open-label, Community Based, Phase 4 Study to Assess Facial Acne Improvement with Use of XXX (XXX gel) Microsphere 0.04% in a Pump Dispenser.
Dec 2006/Aug 2007
SPONSOR: Johnson & Johnson

Phase III Study of the Safety and Efficacy Evaluation of XXX Gel, 0.05%, versus XXX Gel Vehicle in the Treatment of Mild-to-Moderate Acne Vulgaris. Ages 10 and older
2005
SPONSOR: Healthpoint

Phase IV Trial of XXX Gel for Moderate-to-Moderately Severe Facial Acne
2005
SPONSOR: Galderma

XXX vs. XXX Topical Gel for the Treatment of Acne Vulgaris
2005
SPONSOR: Medicis Pharmaceutical Corp

52-week Open-label Study of the Safety of XXX XXX 2% Topical Gel in the Treatment of Seborrheic Dermatitis. First in nation asked to enroll
2004-2005

SPONSOR: Barrier Therapeutics, Inc

Double-blind, Randomized, Vehicle-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of a Topical Gel Product Containing XXX XXX 2% in the Treatment of Seborrheic Dermatitis
2004
SPONSOR: Barrier Therapeutics, Inc

XXX in a Three-stage Dose-escalating Study to Assess Efficacy and Safety for the Treatment of Common Warts in Adults
2004
SPONSOR: 3M Pharmaceuticals

XXX for the Treatment of Menstrual Cycles in Women with Mild-to-Moderate Acne Vulgaris
2003
SPONSOR: Berlex

A Phase II, Randomized, Vehicle-Controlled, Double-Blind, Multi-Center Study to Evaluate Safety and Efficacy of XXX XXX 1.25% and 2.5% Acne Solutions Applied Topically for 12 Weeks to Subjects With Acne Vulgaris
Jan 2003/Sep 2003
SPONSOR: Micrologix BioTech

XXX XXX Pulse-dosing as Treatment of Onychomycosis of the Toenails
2002
SPONSOR: Novartis

15% XXX XXX Cream vs. Vehicle Cream as Topical Treatment for Mild-to-Moderate Acne of the Face
2002
SPONSOR: Berlex Corporation

Topical Patch Application of XXX for Treatment of Onychomycosis
2001-2002
SPONSOR: Watson Pharmaceuticals

XXX XXX vs. XXX in the Treatment of Uncomplicated Skin and Skin Structure Infections
2000
SPONSOR: Bayer Corporation

XXX Cream vs. Vehicle Cream in the Treatment of Plantar Tinea Pedis
2000
SPONSOR: Schering-Plough

XXX vs. Placebo in the Treatment of Patients with Moderate Acne
1999
SPONSOR: Wyeth-Ayerst Laboratories

XXX XXX vs. XXX XXX in the Treatment of Patients with Uncomplicated Skin or Skin Structure Infections
1998

SPONSOR: Tap Holdings, Inc.

Transdermal Delivery of Phenobarbital in Neonates. Manipal, India
1988-1989

Efficacy and Safety of 2% Topical XXX Solution for the Treatment of Male Pattern Alopecia. University of Illinois College of Medicine, Department of Dermatology
1986-1987

Immunohistochemical Staining for EGF Receptors in Nonmalignant Dermatoses with Lloyd E. King, Jr., M.D., Professor in Chief, Division of Dermatology, Vanderbilt University School of Medicine, Nashville, Tennessee
1983-1984